免疫组织化学和聚合酶链反应在乳腺癌易患基因检测中的应用价值  

Evaluation of Immunohistochemistry and PCR in Test of Susceptible Gene of Breast Cancer

作　　者：王振威[1] 吴静[2] 张占东[1] 袁媛[1] 

机构地区：[1]唐山市妇幼保健院普外科,河北唐山063000 [2]唐山市眼科医院内科,河北唐山063000

出　　处：《医学综述》2015年第23期4343-4345,共3页Medical Recapitulate

摘　　要：目的探讨免疫组织化学和聚合酶链反应（PCR）在检测乳腺癌易患基因中的应用价值。方法选取2013年10月至2014年10月唐山市妇幼保健院诊治的乳腺癌患者37例为乳腺癌组，良性乳腺疾病患者37例为良性乳腺疾病组，健康体检者37例为正常组，均行免疫组织化学和PCR检测乳腺癌易患基因。结果乳腺癌组乳腺癌易患基因1、乳腺癌易患基因1／132微球蛋白分别为（1．13±0．51）×10^5拷贝／L、（0．37±0．12），均低于正常组[（3．09±1．38）×10^5拷贝／L、（0．95±0．36）]和良性乳腺疾病组[（2．87±1．40）×10^5拷贝／L、（0．93±0．41）]，差异均有统计学意义（P〈0．05）。乳腺癌组乳腺癌易患基因人表皮因子受体2（Her2）、细胞角蛋白5／6（CK5／6）、表皮生长因子受体（EGFR）分别为（6．75±2．98）×10^9拷贝／L、（25．84±11．43）×10^98贝／L、（43．54±18．26）×10^7拷贝／L，均显著高于正常组[（3．65±1．40）×10^9拷贝／L、（2．69±0．54）×10^8拷贝／L、（2．18±0．90）×10^7拷贝／L]和良性乳腺疾病组[（3．80±1．31）×10^9拷贝／L、（2．76±0．68）×10^8拷贝／L、（2．27±1．04）×10^7拷贝／L]，差异均有统计学意义（P〈0．05）。乳腺癌组β2微球蛋白低于正常组和良性乳腺疾病组。行Her2检测时，PCR检测的灵敏度、特异度、准确度均高于免疫组织化学检测。结论免疫组织化学和PCR检测均可用于乳腺癌易患基因的诊断，其中PCR检测的灵敏度、特异度、准确度更高。Objective To investigate the application value of immunohistochemistryand polymerase chain reaction（PCR） in breast cancer susceptibility gene detection. Methods Total of 37 patients with breast cancer were selected in Tangshan Maternal and Child Health Care Hospital from Oct. 2015 to Oct. 2014 were included as breast cancer group,37 patients with benign breast disease were included as benign breast disease group, and 57 healthy persons as normal group. All people received breast cancer susceptibility gene detection of immunohistochemistry and PCR. Results Breast cancer susceptibility gene 1, breast cancer susceptibility gene 1/132 microglobuliu in the breast cancer group were （ 1.13 ±0. 51 ） ×10^5 copies/L, （0.37 ±0. 12） ,both lower than the control group [ （3.09 ± 1.38） ×10^5 copies/L, （0. 95 ±0. 36） ] and benign breast disease group [ （2. 87± 1.40） ×10^5 copies/L, （0. 93 ±0. 41 ） ] ,the differences were statistically significant（P 〈 0. 05 ）. Breast cancer susceptibility genes human epidermal growth factor receptor 2 （Her2）, cytokeratin 5/6 （CK5/6）, epidermal growth factor receptor （EGFR） in breast cancer group were （6.75 ± 2.98 ） ×10^9 copies/L, （25.84± 11.43 ） ×10^8 copies/L, （43.54 ± 18.26 ） ×10^7 copies/L respectively,significantly higher than the normal group [ （3.65±1.40） ×10^9 copies/L, （2. 69 ±0. 54） ×10^8 copies/L, （2. 18± 0. 90）×10^7 copies/L ] and benign breast disease group [ （3.80 ± 1.31 ） ×10^9 copies/L, （2. 76 ±0. 68）×10^8 copies/L, （2. 27 ± 1.04） ×10^7 copies/L] ,the differences were statistically significant （ P 〈 0. 05 ）. β2 microglobulin in breast cancer group was lower than the normal group and benign breast disease group. As for Her2 line detection, the sensitivity, specificity, and accuracy of PCR assay were higher than immunohistochemistry. Conclusion Both immunohistochemistry and PCR can be used to for breast cancer susceptibility gene detection, and PCR detection has higher

关 键 词：乳腺癌 免疫组织化学 聚合酶链反应 易患基因 评估 

分 类 号：R737[医药卫生—肿瘤] R446[医药卫生—临床医学]